Skip to main content
    E

    Exagen Inc (XGN)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $3.76
    -0.01 (-0.27%)

    Market Cap: $96.19M

    Last updated: Nov 17, 2026 at 4:13 PM ET

    Exagen Inc (XGN) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Exagen (XGN) has a market cap of $96.19M and an enterprise value of $90.91M. Its share count is up 8.32% from a year earlier. It kept -25.14% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 5.49% below the market cap, as cash exceeds debt.

    Market Cap$96.19M
    Enterprise Value$90.91M
    Latest price (Nov 17, 2026)$3.76

    Key Dates

    The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 8, 2027 (expected)
    Last Earnings DateNov 10, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 2.84% in the quarter ended Sep 30, 2026 and grew 16.67% a year over 2 years.

    Shares Outstanding24.85M
    Shares Change (YoY)+8.32%
    Shares Change (QoQ)+2.84%
    Share Count Growth (2Y CAGR)+16.67%

    Valuation Ratios

    Sales and book value multiples are 1.3x and 6.8x. Its year-end P/S ranged from 0.7x to 4.0x from 2020 to 2025.

    P/S Ratio1.3x
    Forward P/S1.3x
    P/B Ratio6.8x

    Valuation history and multiples

    Price Statistics

    The stock is down 58.27% over 52 weeks and trades 50.26% below its 50-day average.

    Beta (1Y)2.67
    52-Week Change-58.27%
    1-Month Change-49.39%
    3-Month Change-49.39%
    6-Month Change+0.80%
    5-Year Change-26.08%
    Total Return (1Y)-58.27%
    Total Return (3Y CAGR)+33.73%
    Total Return (5Y CAGR)-21.05%
    Return vs SPY (1Y)-65.76%
    Max Drawdown (1Y)-68.71%
    Max Drawdown (3Y)-77.84%
    Sharpe Ratio (1Y)-0.85
    Correlation with SPY (1Y)0.40
    50-Day Average$7.56
    200-Day Average$5.12
    52-Week Range$2.59 to $9.22
    RSI (14 Days)27.3
    Average Volume (20 Days)781.74K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.46x current liabilities, and total debt is 1.66x shareholder equity.

    Current Ratio3.46x
    Quick Ratio3.46x
    Debt / Equity1.66x
    Interest Coverage-2.95x

    Returns and Efficiency

    Return on invested capital is -40.37% over the last 12 months, against a 5-year average of -44.80%.

    Return on Equity (ROE)-131.92%
    Return on Assets (ROA)-32.83%
    Return on Invested Capital (ROIC)-40.37%
    Return on Capital Employed (ROCE)-34.96%
    ROA (5Y Average)-37.30%
    ROIC (5Y Average)-44.80%
    Asset Turnover1.22x
    Receivables Turnover6.05x

    Scores

    XGN has an Altman Z-Score of -5.82, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score-5.82
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $72.30M over the last 12 months is up 13.67% from the 12 months before.

    Revenue$72.30M
    Revenue Growth (YoY)+13.67%
    Gross Profit$42.46M
    Operating Income-$14.52M
    Pretax Income-$18.12M
    Net Income-$18.17M
    EBITDA-$10.45M
    EBIT-$14.77M
    Reported EPS (TTM)-$0.85

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 24.90% of the $55.35M in total assets.

    Cash and Equivalents$28.09M
    Total Debt$22.81M
    Net Cash$5.28M
    Net Cash Per Share$0.21
    Working Capital$32.23M
    Shareholder Equity$13.78M
    Book Value Per Share$0.55
    Total Assets$55.35M
    Total Liabilities$41.58M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $1.01M of capital spending, operating cash flow left -$13.03M of free cash flow.

    Operating Cash Flow-$12.02M
    Capital Expenditures$1.01M
    Free Cash Flow-$13.03M
    FCF Per Share-$0.54
    Depreciation and Amortization$4.32M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -20.08%, against a 5-year average of -48.00%.

    Gross Margin58.74%
    Operating Margin-20.08%
    Pretax Margin-25.07%
    Net Margin-25.14%
    EBITDA Margin-14.45%
    EBIT Margin-20.43%
    FCF Margin-18.02%
    Gross Margin (5Y Average)55.61%
    Operating Margin (5Y Average)-48.00%
    Net Margin (5Y Average)-52.36%

    Growth

    Revenue grew 13.47% a year over 3 years.

    Revenue Growth (3Y CAGR)+13.47%
    Revenue Growth (5Y CAGR)+9.66%
    Book Value Per Share Growth (2Y CAGR)-20.24%
    Tangible Book Per Share Growth (2Y CAGR)-20.24%

    Revenue and profit by year

    Dividends and Yields

    XGN does not pay a dividend. Its free cash flow yield is -13.94%.

    FCF Yield-13.94%
    Buyback Yield-7.40%
    Shareholder Yield-7.40%

    Peer Position

    Against 10 similar companies, XGN has the 9th highest P/S and the 9th highest ROIC.

    P/S Ratio1.3x vs 4.5x median
    ROIC-40.37% vs 5.79% median
    Revenue Growth (Trailing 4 Quarters, YoY)+13.67% vs +11.87% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 9.72% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+9.72%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About XGN

    What is XGN's market cap?

    Exagen has a market cap of $96.19M. Its enterprise value, which adds debt and subtracts cash, is $90.91M.

    How many shares of XGN are outstanding?

    Exagen has 24.85M shares outstanding. The count is up 8.32% from a year earlier.

    Does XGN pay a dividend?

    No. Exagen does not pay a dividend.

    How much debt does XGN have?

    Exagen has $22.81M of total debt and $28.09M of cash and equivalents, a net cash position of $5.28M.